



The Kintec Group Presents

Current Concepts Review on Management of Recalcitrant Plantar Fasciitis

PRESENTERS

Kaila Holtz MD FRCPC

Dip Sports Med and Title
Physiatrist & Medical Director, Triumph Health

Dr. Michael Ryan, PhD, C. Ped (C)

VP Brand & Innovation, Kintec Footwear & Orthotics



OFFICIAL SUN RUN FOOTWEAR & ORTHOTICS RETAILER

 **kintec**
FOOTWEAR + ORTHOTICS




VANCOUVER
SUN

2023 SUN RUN VIP



2024 SUN RUN VIP






Metatarsalgia: Clinical Profile and Comfort from Foot Orthoses Treatment. Robb K & Ryan M. 2024 Accepted


Custom VDOO

Customize arch
contouring




Indicate lateral
wedge angle

Customize foot/ankle
support



3D PRINTING



Social Media Stats and Reach



Waterloo Store Opening

Social Media



Whitby Store Opening



Vernon Store Opening



PLANTAR FASCIOPATHY (A.K.A. PLANTAR FASCIITIS)


Michael Ryan PhD, C Ped (C)

Director Research and Development, Kintec


Adjunct Professor, BPK Dept, SFU



PREAMBLE



Plantar view



Plantar digital arteries proper

Common plantar digital arteries

Lumbrical muscles (*cut*)

Deep transverse metatarsal ligament and plantar ligaments (plates)

Interossei muscles { **Plantar**
Dorsal

Abductor digiti minimi muscles (*cut*)

Plantar metatarsal arteries

Flexor digiti minimi brevis muscle

Deep plantar arch

Lateral plantar artery (*cut*)

Tuberosity of 5th metatarsal bone

Fibularis (peroneus) longus tendon

Fibularis (peroneus) brevis tendon (*cut*)

Tuberosity of cuboid bone

Long plantar ligament

Calcaneocuboid (short plantar) ligament

Anterior perforating branches (to dorsal metatarsal arteries)

Sesamoid bones

Insertion of adductor hallucis and lateral head of flexor hallucis brevis muscles (*cut*)

Insertion of abductor hallucis and medial head of flexor hallucis brevis muscles (*cut*)

Medial origin of flexor hallucis brevis muscle (*cut*)

Deep plantar artery (from dorsalis pedis artery)

Posterior perforating branches (to dorsal metatarsal arteries)

Plantar metatarsal ligaments (between bases of metatarsal bones)

Medial cuneiform bone


Tibialis anterior tendon (*cut*)


Lateral origin of flexor hallucis brevis tendon (*cut*)


Tuberosity of navicular bone

Tibialis posterior tendon (*cut*)



Plantar calcaneonavicular (spring) ligament







PLANTAR FASCIOPATHY




Original article

Sonographically guided intratendinous injections of hyperosmolar dextrose/lidocaine: a pilot study for the treatment of chronic plantar fasciitis

M B Ryan,¹ A D Wong,² J H Gillies,³ J Wong,⁴ J E Taunton⁵



Plantar fasciitis & Foot Posture



FPI = 12



FPI = -5





THERAPEUTIC APPROACHES

TREATMENT

- If **plantar fasciopathy**, need to address
 1. Pain
 2. Intrinsic muscle activation
 3. Plantar fascia rehabilitation



FOOT ORTHOSES

Review

Management of plantar heel pain: a best practice guide informed by a systematic review, expert clinical reasoning and patient values

Dylan Morrissey ,^{1,2} Matthew Cotchett ,³ Ahmed Said J'Bari,¹ Trevor Prior,¹ Ian B Griffiths ,¹ Michael Skovdal Rathleff,⁴ Halime Gulle,¹ Bill Vicenzino ,⁵ Christian J Barton ^{3,6}

Conclusions: Best practice from a mixed-methods study suggests....patients who do not optimally improve may be offered shockwave therapy, followed by orthoses.



ARE THESE THE SAME?



=



=



KIWI DATABASE


Sample size: 4,954

% change in pain from assessment: 58%

GLOBAL RATE OF CHANGE

Not including adjustments


- Improved
- No Change
- Worse




ORTHOTICS USAGE

Frequency of usage

- Greater than 6 hours per day
- 4-6 hours per day
- 1-3 hours per day
- Couple times per week
- Couple times per month
- Never wear the orthotics



ROCKER SHOES



PLANTAR FASCIA-SPECIFIC STRETCHING EXERCISE IMPROVES OUTCOMES IN PATIENTS WITH CHRONIC PLANTAR FASCIITIS


A PROSPECTIVE CLINICAL TRIAL WITH TWO-YEAR FOLLOW-UP


BY BENEDICT F. DIGIOVANNI, MD, DEBORAH A. NAWOCZENSKI, PhD, PT, DANIEL P. MALAY, MSPT,
PETRA A. GRACI, DPT, TARYN T. WILLIAMS, MSPT, GREGORY E. WILDING, PhD, AND JUDITH F. BAUMHAUER, MD



Examining the Degree of Pain Reduction Using a Multielement Exercise Model with a Conventional Training Shoe Versus an Ultraflexible Training Shoe for Treating Plantar Fasciitis

Michael Ryan, PhD; Scott Fraser, BSc, PT; Kymberly McDonald, BSc; Jack Taunton, MD, MSc






 Allan McGavin
 Sports Medicine Centre



Comparison of a Physiotherapy Program Versus Dexamethasone Injections for Plantar Fasciopathy in Prolonged Standing Workers: A Randomized Clinical Trial

Michael Ryan, PhD,† Jamie Hartwell, BKin,* Scott Fraser, PT,*
 Richard Newsham-West, MPhty, PhD,† and Jack Taunton, MD**

NIGHT SPLINTS



CURRENT CONCEPTS

Management of Recalcitrant Plantar Fasciitis



Kaila A. Holtz, MSc MD FRCPC
Clinical Assistant Professor, Dip Sports Med
Division of Physical Medicine and Rehabilitation
University of British Columbia Faculty of Medicine



Kintec Community Event
March 6, 2024

DISCLOSURES

Neither I, Dr. Kaila A. Holtz, nor any family member(s), have any relevant financial relationships to be discussed, directly or indirectly, referred to or illustrated with or without recognition within the presentation.





OBJECTIVES

By the end of the session, you will be able to:

1. Describe the pathophysiology of plantar fasciitis;
2. Describe the basic principles behind orthobiologic treatments (ESWT, dextrose microtenomy, PRP);
3. Counsel a patient regarding the pro's and con's of interventional treatment for plantar fasciitis;
4. Offer your patients some insights where orthobiologic injections might fit into their treatment plan.







Normal plantar fascia. A schematic representation (a) and lateral plain radiograph (b) show the normal PF (arrows). On sagittal ultrasound scan, the normal PF (arrows) appears as a fibrillar ligamentous structure (c). On MRI, the normal PF (arrows) is seen as a thin band of low signal intensity on both T1-weighted (d) and fluid-sensitive (e) images

INTRODUCTION – PLANTAR FASCIITIS



Single most common cause of heel pain.

Affects approx 10% of the population (lifetime risk).

Higher incidence among individuals ages 45 to 65 years.

Risk Factors:

- Standing occupations (e.g. military personnel)
- Long distance runners
- Obesity
- Tight gastrocnemius/soleus complex
- Pes planus

Hasegawa, M., Urits, I., Orhurhu, V. *et al.* Current Concepts of Minimally Invasive Treatment Options for Plantar Fasciitis: a Comprehensive Review. *Curr Pain Headache Rep* **24**, 55 (2020).

PATHOPHYSIOLOGY OF PLANTAR FASCIITIS





Fig. 6. Inflammation of plantar fascia. Microtrauma causes macrophages to release inflammatory cytokines which incite the inflammatory process. T-Cells and NK cells are signaled to the site of injury via chemotaxis; they migrate from the bloodstream into the tissue via diapedesis. The presence of T-cells and NK cells at the site of injury further propagates the inflammatory process.

Rabadi D, Seo S, Wong B, Chung D, Rai V, Agrawal DK. Immunopathogenesis, early Detection, current therapies and prevention of plantar Fasciitis: A concise review. *Int Immunopharmacol.* 2022 Sep;110:109023.




Plantar fasciitis. Lateral plain radiograph highlights an increase in the distance between subcutaneous fat and intrinsic muscles of the foot at the calcaneal insertion of the PF as an indirect sign of plantar fasciitis (*double-head arrow*); calcific enthesopathy of the Achilles tendon is also seen (*open arrow*) (a). On ultrasound, plantar fasciitis presents with PF thickening (*dashed line*, 6.5 mm), a hypoechoic appearance and loss of fibrillar pattern (b). MRI confirms thickening of the PF at its calcaneal origin (*double-head arrow*) with intrasubstance areas of intermediate and high signal intensity on T1-weighted (c) and fluid-sensitive (d) images, respectively

CLINICAL PRESENTATION



- Classic symptom is pain in the mornings when rising from bed.
- Pain that originates at the heel.
- Restricted ankle dorsiflexion (risk fac

Positive windlass test



EVIDENCE BASED NON-INVASIVE TREATMENT



Treatment	Mechanism	Evidence Level
NSAIDS	Reduced prostaglandins by inhibiting COX-1/COX-2	B
Custom Orthotics	Reduces shock through the plantar fascia	B
Rocker bottom shoes	Reduces stress through the arch	B
Achilles stretching Plantar stretching Night Splints	Reduces migration of inflammatory cells Reduces risk factors	B

CASE EXAMPLE



CASE EXAMPLE

45-year-old man referred to me with plantar fasciitis referred for cortisone injection?

Risk Factors:

- Recreational runner
- Pes planus
- Walking at work (construction site)

Treatments tried:

- Achilles stretching
- Diclofenac 10%
- Physiotherapy – manual therapy, strengthening, taping



CASE EXAMPLE

On examination,

- Normal neurological examination.
- Pes planus.
- Normal gastrocnemius/soleus complex.
- Maximally tender to the medial tuberosity of the calcaneus.
- Non tender to other structures of the foot, particularly the tarsal tunnel, Achilles insertion, abductor hallucis (Baxter's nerve), etc.
- Positive Windlass maneuver.

Clinical diagnosis: Plantar fasciitis/fasciosis

Goal # 1: Identify gaps in treatment plan!




PLANTAR FASCIITIS MANAGEMENT

Treatment	Where/How?	Duration
NSAIDS	Topical diclofenac 10% twice daily to medial heel	14 days
Custom Orthotics Night Splints	Local pedorthotist clinic	2-3 months
Rocker bottom shoes	Local pedorthotist clinic/footwear store	2-3 months
Achilles stretching Plantar stretching	Physiotherapy	2-3 months

If after 6 months, second line measures




REGENERATIVE MEDICINE



Regenerative medicine focuses on developing and applying new treatments to heal tissues and organs to restore function lost due to aging, disease, damage or defects. (Mayo.edu)

RELEVANT TERMS



*not approved by Health Canada

EXTRACORPOREAL SHOCKWAVE THERAPY (ESWT)



Non-invasive therapy that sends acoustic shockwaves to tissues that results in mechano-transduction within the tissue leading to the production of free radicals that induce growth factors in the tissue.

- Collagen synthesis
- Cellular proliferation
- Pain reduction


PROLOTHERAPY

Solutions range from 12.5 – 25% Dextrose


Been used safely for more than 80 years. It was popularized by Dr. George Hackett, a general surgeon in the U.S, in the 1950's who was an expert in disability assessments.

Used as an off-label substance.

Goal of treatment: to augment the tensile strength of joint-stabilizing structures like ligaments and tendons.



BASIC PRINCIPLES OF PROLOTHERAPY



Wound Healing Cascade²

PLATELET RICH PLASMA - PRP


Solution of autologous human plasma with increased platelet concentrations.

Obtained by centrifuging or separating a large volume (usually 60 to 120mL) of blood and extracting specific layers.


Classified as a **drug** by Health Canada.

Does **NOT** contain “stem cells”.

Goal of treatment: to augment the natural healing process with supraphysiologic amounts of growth factors by injecting platelets at/into an injury site.



COMPOSITION OF PLATELET RICH PLASMA




EXAMPLE OF COMMERCIAL PRP SYSTEM




WHAT ARE THE “ACTIVE” COMPONENTS OF PRP?

PRP is defined as a platelet rich concentrate with higher than baseline levels of platelets relative to whole blood.



BASIC PRINCIPLES OF PLATELET RICH PLASMA INJECTIONS



Wound Healing Cascade

SUMMARY - ORTHOBIOLOGICS

List the most commonly used orthobiologic injections for musculoskeletal pain in Canada.

1. Prolotherapy
2. Platelet Rich Plasma (PRP)

Describe the **basic principles** behind orthobiologic injections.

Prolotherapy **starts** the inflammatory cascade by causing by local tissue trauma. PRP **augments it with supraphysiologic concentrations of platelets**, anti-inflammatory cells, growth factors and neuropeptides.



EVIDENCE FOR INTERVENTIONS IN PLANTAR FASCIITIS



Dextrose prolotherapy versus radial extracorporeal shock wave therapy in the treatment of chronic plantar fasciitis: A randomized, controlled clinical trial

Mahsa Asheghan^{a,*}, Seyed Ebrahim Hashemi^a, Mohammad Taghi Hollisaz^a, Peiman Roumizade^b, Seyed Morteza Hosseini^c, Ali Ghanjal^d

^aExercise Physiology Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran

^bDepartment of Physical Medicine and Rehabilitation, Iran University of Medical Sciences, Tehran, Iran

^cMedicine, Quran and Hadith Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran

^dHealth Management Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran

Table 1

The baseline demographic and clinical characteristics of the patients.

Journal of Foot
N=29, ESW
Patients had
consecuti

Variable	ESWT (n = 29)	Prolotherapy (n = 30)	P value
Age (years)	43.7 ± 7.6	46.5 ± 6.5	0.133
Gender (female/male)	20/9	19/11	0.647
Disease duration (months)	4.8 ± 1.2	4.5 ± 1.3	0.361
BMI (kg/m ²)	26.5 ± 3.6	25.3 ± 4.2	0.244
VAS	72.32 ± 13.1	74.6 ± 11.1	0.387
FAAM-ADL (0–100)	74.2 ± 10.2	72.4 ± 12.6	0.543
FAAM-Sport (0–100)	72.6 ± 12.3	70.1 ± 11.8	0.428
Thickness (mm)	4.5 ± 0.6	4.7 ± 0.4	0.132

atrist)

Abbreviations: BMI—Body mass index; VAS—Visual analogue scale; FAAM—Foot and ankle ability measure; ADL—Activities of daily living.

Table 2

The effects of the ESWT and prolotherapy on the VAS, FAAM questionnaire, and plantar fascia thickness (N = 59 feet).

Variable	Time of intervention	Intervention	Mean	SD	P-Value	P-Value	
VAS	Baseline	ESWT	72.32	13.16	Group and Time Interaction	0.231	Baseline vs.12 weeks
		Prolotherapy	74.66	11.15			
	After 6 weeks	ESWT	56.55	12.52			
		Prolotherapy	53.31	10.11			
	After 12 weeks	ESWT	40.82	10.32			
		Prolotherapy	44.22	9.5			
FAAM-ADL	Baseline	ESWT	74.2	10.2	Group and Time Interaction	0.287	Baseline vs.12 weeks
		Prolotherapy	72.4	12.8			
	After 6 weeks	ESWT	88.3	7.2			
		Prolotherapy	87.5	8.7			
	After 12 weeks	ESWT	91.3	6.8			
		Prolotherapy	90	8.9			
FAAM-sport	Baseline	ESWT	72.6	12.3	Group and Time Interaction	0.038	Baseline vs.12 weeks
		Prolotherapy	70.1	11.8			
	After 6 weeks	ESWT	88.7	11.1			
		Prolotherapy	83.3	10.8			
	After 12 weeks	ESWT	92.3	10.2			
		Prolotherapy	85.8	9.3			
Fascia thickness	Baseline	ESWT	4.5	0.6	Group and Time Interaction	0.532	Baseline vs.12 weeks
		Prolotherapy	4.7	0.4			
	After 6 weeks	ESWT	4	0.3			
		Prolotherapy	4.1	0.3			
	After 12 weeks	ESWT	3.8	0.3			
		Prolotherapy	3.7	0.4			

Abbreviations: VAS—Visual analogue scale; ESWT—Extracorporeal shock wave therapy; FAAM—Foot and ankle ability measure; ADL—Activities of daily living.



Both groups showed significant decreases in pain scores and improvements in function and plantar fascia thickness. No superior treatment

SYSTEMATIC REVIEW AND META-ANALYSIS

Platelet rich plasma therapy versus other modalities for treatment of plantar fasciitis: A systematic review and meta-analysis

Agustin Herber ^{a,*}, Oscar Covarrubias ^b, Mohammad Daher ^b, Wei Shao Tung ^c,
Arianna L. Gianakos ^c

^a Department of Surgery, University of Arizona College of Medicine – Phoenix, Phoenix, AZ 85004, USA

^b Department of Orthopedics, Brown University, Providence, RI 02906, USA

^c Department of Orthopaedics and Rehabilitation, Yale University, New Haven, CT 06510, USA

N=21 articles; PRP vs. other modalities, total subjects = 1356 patients

Outcomes:

- Visual analog scale
- Plantar thickness
- Functional scores (Foot Function Index and American Orthopedic Foot and Ankle Society)
- Follow-up > 12 weeks






Fig. 3. Forest plot showing the improvement of VAS.

OTHER OUTCOMES

Plantar fascia thickness (N=456)

- No significant differences in fascia thickness among treatment modalities

Foot Function Index (N=105)

- PRP > phonophoresis
- No significant differences between PRP and other treatment modalities.

American Orthopedic Foot and Ankle Society (AOFAS) Score (N=637)

- PRP > cortisone, and placebo
- No significant differences between PRP and other treatment modalities.



APPLYING EVIDENCE TO PATIENTS

Shockwave therapy is not inferior to dextrose microtenotomy.

- Accessibility in community is reasonable. I usually suggest patients seek out a practitioner close to their work or home.



Trial of dextrose prolotherapy is less costly than PRP.

- In my clinical experience, if people respond to prolotherapy, they are more likely to respond to PRP.
- Usually 2-4 injections, 6 weeks apart vs. 1 PRP injection.

Shockwave can be used to augment orthobiologic injections.

Before PRP, always get advanced imaging.

- Tarsal tunnel syndrome
- Complex tears
- Infection

Summary



Intervention Type	PROS	CONS
Steroid	Cheap	Detrimental to structure, not used much anymore
ESWT	Non-invasive	Requires sessions weekly over 6-8 weeks.
Dextrose prolotherapy	Improves pain, effect vs. PRP unknown	Difficult to access in community, variable costs.
PRP	Superior to other treatments (CSI and shockwave)	\$\$\$

OBJECTIVES

By the end of the session, you will be able to:

- ✓ Describe the pathophysiology of plantar fasciitis;
- ✓ Describe the basic principles behind orthobiologic treatments (ESWT, dextrose prolotherapy, PRP);
- ✓ Counsel a patient regarding the pro's and con's of interventional treatment for plantar fasciitis;
- ✓ Offer your patients some insights where orthobiologic injections might fit into their treatment plan.

ACKNOWLEDGEMENTS

Mentors

Dr. Arun Gupta, PM&R University of Calgary

Dr. Jason Crookham, Sports Medicine, POSM

Dr. Rob Drapala, Sports Medicine, Allan McGavin Sports Medicine

Dr. Luck Louis, Radiology, UBC Hospital





Kaila A. Holtz, MSc MD FRCPC
Physical Medicine and Rehabilitation Specialist
kholtz@triumphhealth.com



Find me
on:

